Cuscal (CCL) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
25 Mar, 2026Executive summary
Consolidated Profit After Tax rose 21% year-over-year to $31.6m, with adjusted EBITDA up 22% to $56.2m and Net Operating Income up 18% to $284.5m, driven by transaction growth, new clients, and higher net interest income.
A significant non-recurring benefit from a fair value adjustment on the Basiq acquisition option liability was partially offset by increased consulting, legal, and integration costs.
The company maintained a strong capital position, with a capital adequacy ratio of 22.3% and an upgraded AA- credit rating.
A final fully franked dividend of 5.0 cents per share was declared, bringing the full-year dividend to 8.5 cents per share, a 13% increase year-over-year.
The company is progressing towards a potential IPO by the end of 2024 to access deeper funding and support growth initiatives.
Financial highlights
Net Operating Income increased 18% to $284.5m, with transaction volumes up 6% year-over-year.
Operating expenses rose 19% to $241.9m, reflecting higher employment costs, consulting, legal, and integration expenses.
Adjusted EBITDA grew 22% to $56.2m, and EPS increased 21% to 18.0 cents per share.
Return on Equity improved to 10.2% from 8.8% last year.
Regulatory capital ratio at 22.3%, well above minimum requirements.
Outlook and guidance
Forecasts stable core business growth in FY2025, driven by transaction volume increases and new business onboarding.
Focus on enhancing technology, operational resilience, and risk management, including CPS 230 compliance and fraud/scam capability.
Full-year FY2025 dividend expected in the range of 9.0–11.0 cents per share, subject to board discretion.
IPO process to recommence, targeting completion before end of 2024.
Latest events from Cuscal
- NPAT up 76%, underlying NPAT up 13%, and FY26 outlook raised after Indue acquisition.CCL
H1 202624 Feb 2026 - Pro forma NPAT up 42% to $21.5m, with 7% transaction volume growth and strong capital.CCL
H1 202511 Oct 2025 - FY25 results beat forecasts; Indue acquisition to deliver major cost synergies and EPS growth.CCL
H2 202511 Oct 2025 - Strong H1 FY25 growth and innovation position the business for further expansion.CCL
ASX SMIDcaps Conference Presentation8 Oct 2025